Similar to observations from myeloma, breast, and ovarian cancer models (47, 51–53), both drugs caused dose-dependent suppression of proliferation and FOXM1 expression, while altering gene expression in a manner consistent with FOXM1 inhibition (Figure 6, D–F, and Supplemental Figure 7, D and E). This evidence concerns the gene FOXM1 and plasma cell myeloma.